CN110038023A - A kind of pharmaceutical composition for the antiallergic activity substituting the achene of Siberian cocklebur - Google Patents
A kind of pharmaceutical composition for the antiallergic activity substituting the achene of Siberian cocklebur Download PDFInfo
- Publication number
- CN110038023A CN110038023A CN201910318368.5A CN201910318368A CN110038023A CN 110038023 A CN110038023 A CN 110038023A CN 201910318368 A CN201910318368 A CN 201910318368A CN 110038023 A CN110038023 A CN 110038023A
- Authority
- CN
- China
- Prior art keywords
- achene
- siberian cocklebur
- antiallergic activity
- drug
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
The invention discloses a kind of pharmaceutical compositions of antiallergic activity for substituting the achene of Siberian cocklebur to carry out antiallergic effect card according to chlorogenic acid, caffeic acid cholinester and achene of Siberian cocklebur thiazine diketone three compounds of glycosides, and composition drug effect contribution rate is 78.3%.The present invention applies upper patent protection in antiallergic with regard to chlorogenic acid, caffeic acid cholinester and achene of Siberian cocklebur thiazine diketone glycoside composition.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, in particular to a kind of pharmaceutical compositions of antiallergic activity.
Background technique
Allergic rhinitis (allergic rhinitis, AR) are also known as allergic rhinitis, are ENT & HN Surgery Dept. fields
Common frdquently encountered disease.ARIA (Allergic Rhinitis and Its Impact on Asthma, 2001) points out the disease generation
Illness rate within the scope of boundary is about in 15%-20%.China lacks nationwide epidemic data, portion centers city
Initial investigation results show that its illness rate is 5% or so.The prevalence of allergic disease and social environment, economic shape locating for crowd
The factors such as condition and life style have close relationship, and the allergic rhinitis disease incidence of developed country is generally apparently higher than development
Middle country or undeveloped country, it is contemplated that with the continuous social and economic development, the profound change of environment and life style,
Allergic rhinitis disease incidence is possible to that continuous upward trend is presented in China；Allergic rhinitis seriously affect the life matter of patient
Amount and working efficiency, especially can adversely affect children's study ability, attention, disposition etc.；And it often with branch gas
The merging such as pipe asthma, conjunctivitis, nasosinusitis and tympanitis exist, and should cause clinical enough attention；In terms of health economics
Consider, allergic rhinitis also can not be ignored to financial burden caused by patient.Therefore, research treatment allergic rhinitis are safe and effective
Cheap drug is facilitated to have important practical significance.
The achene of Siberian cocklebur is fruit of the drying and ripening with involucre of compositae plant Siberian cocklebur Xanthium sibiricum Patr., tool
There is the effect of dispersing wind and cold, clearing the nasal passage, wind-damp dispelling, be the active drug treating wet three gas of chill and being hurt, spy is good at dispelling wind, is used for
Anemofrigid headache, nasal congestion, allergic rhinitis, nasosinusitis, rubella itch, arthritis with fixed pain caused by dampness muscular constricture etc., Starch 1500 mountain peak is pushed up in addition, and relieve heat of dispelling is evil, is clinical
The key medicine of upper treatment allergic rhinitis, there is good research and development prospect.
But the achene of Siberian cocklebur with fruit medicine there are complicated component, effective component is indefinite, the uppity defect of quality.
If can find can substitute the composition that the achene of Siberian cocklebur is used as medicine, so that it may which manually mode controls pharmaceutical composition accurately to replace
Be used as medicine for the achene of Siberian cocklebur, at distinguish one from the other, it is quality controllable.At present, in this case it is not apparent which kind combination of those ingredients can be in the achene of Siberian cocklebur
The drug effect in antiallergic activity of the basic substitution achene of Siberian cocklebur.
With regard to chlorogenic acid, caffeic acid cholinester and achene of Siberian cocklebur thiazine diketone glycoside composition, the composition has very strong the present invention
Antiallergic activity, so far, there has been no patent or document reports for the above research achievement.The present invention is in antiallergic using upper
Patent protection.
Summary of the invention
The technical problem to be solved by the embodiment of the invention is that providing a kind of medicine of antiallergic activity for substituting the achene of Siberian cocklebur
Compositions.
To achieve the above object, the technical scheme is that it is double by chlorogenic acid, caffeic acid cholinester and achene of Siberian cocklebur thiazine
Ketoside composition.
Further setting be chlorogenic acid, caffeic acid cholinester, achene of Siberian cocklebur thiazine diketone glycosides mass ratio be 2.744:
2.233:0.743.
The present invention also provides application of the above-mentioned composition in terms of preparing antiallergic activity drug.
It further includes the drug ingedient or carrier for having other medically acceptable that further setting, which is the antiallergic activity drug,
The mass ratio that the chlorogenic acid accounts for the antiallergic activity drug is that 2.744%, caffeic acid cholinester accounts for the antiallergic activity medicine
The mass ratio of object is 2.233%, to account for the mass ratio of the antiallergic activity drug be 0.743% to achene of Siberian cocklebur thiazine diketone glycosides.It is described
Medically acceptable drug ingedient or carrier component proportion can be carried out according to the existing reference book of doctor's allusion quotation etc. or existing drug,
It is the ordinary skill in the art.
Beneficial effect of the present invention and Innovation Mechanism are:
The present invention relates to related to antiallergy drug effect to achene of Siberian cocklebur difference extract high performance liquid chromatography (HPLC) map
Property, it is found that chlorogenic acid, caffeic acid cholinester and the achene of Siberian cocklebur thiazine diketone glycosides in the achene of Siberian cocklebur are the antianaphylactic drug effect objects of the achene of Siberian cocklebur
Containing in product alcohol extract is being fried according to chlorogenic acid, caffeic acid cholinester and three compounds of achene of Siberian cocklebur thiazine diketone glycosides in matter basis
(content of caffeoyl cholinester is 2.233% to the artificial preparation effective component composition of amount；The content of chlorogenic acid is 2.744%；It is grey
The content of ears or side handles of a utensil thiazine diketone glycosides is 0.743%), to carry out antiallergic effect card, and quality is 5.72% group of stir-fry product alcohol extract
Conjunction object drug effect contribution rate is stir-fry product alcohol extract 78.3%.The present invention is with regard to chlorogenic acid, caffeic acid cholinester and achene of Siberian cocklebur thiazine diketone
Glycoside composition applies upper patent protection in antiallergic.
By the correlation of achene of Siberian cocklebur difference extract high performance liquid chromatography (HPLC) map and antiallergy drug effect, with histamine
For inhibiting rate as antiallergy pharmacodynamics evaluation index, investigating achene of Siberian cocklebur difference extract stimulates rat abdomen to Compound 48/80
The influence of chamber mast cell degranulation releasing histamine, with partial least-squares regression method by HPLC map peak area and antiallergy drug effect
Data correlation, research spectrum effect correlation, calculates the material base for inferring achene of Siberian cocklebur anti-allergic effects, and with being verified.
The present invention is the result shows that achene of Siberian cocklebur anti-allergic effects are chlorogenic acid, caffeic acid cholinester and achene of Siberian cocklebur thiazine diketone three ingredients of glycosides
It is coefficient as a result, and it is in close relations with its characteristic component, multicomponent collective effect effect be better than single ingredient function and effect
The sum of.
It is specifically shown in embodiment experimental data.
Detailed description of the invention
In order to more clearly explain the embodiment of the invention or the technical proposal in the existing technology, to embodiment or will show below
There is attached drawing needed in technical description to be briefly described, it should be apparent that, the accompanying drawings in the following description is only this
Some embodiments of invention, for those of ordinary skill in the art, without any creative labor, according to
These attached drawings obtain other attached drawings and still fall within scope of the invention.
The comparison figure of histamine inhibiting rate in Fig. 1 embodiment of the present invention two；
The chromatography of Fig. 2 embodiment of the present invention three compares figure；
Drug effect contribution rate of the six groups of extract X of Fig. 3 achene of Siberian cocklebur to Y.
Specific embodiment
To make the object, technical solutions and advantages of the present invention clearer, the present invention is made into one below in conjunction with attached drawing
Step ground detailed description.
The preparation of one xanthium sibiricum of embodiment
Achene of Siberian cocklebur medicine materical crude slice 1000g is weighed, appropriateness crushes, and is divided into two parts, and portion is extracted 2 times with 10 times of amount deionized waters,
Liquid extract is concentrated under reduced pressure to obtain in each 1h, combined extract, and 50 DEG C of vacuum drying obtain achene of Siberian cocklebur medicine materical crude slice (frying product) water extract
(CP-W)56.3g；Another is extracted 2 times, each 1h with 10 times of 75% ethyl alcohol of amount, and liquid extract is concentrated under reduced pressure to obtain in combined extract,
50 DEG C of vacuum drying obtain the achene of Siberian cocklebur and fry product alcohol extract (CP-E) 41.5g；The remaining dregs of a decoction dry after alcohol extracting, with 10 times of amounts go from
Sub- water extracts 2 times, each 1h, combined extract, and liquid extract is concentrated under reduced pressure to obtain, and 50 DEG C of vacuum drying obtain the achene of Siberian cocklebur and fry product alcohol
Water extract (CP-EW) 21.2g afterwards.Achene of Siberian cocklebur medicinal material (health product) 1000g is weighed to obtain by processing identical with achene of Siberian cocklebur medicine materical crude slice
To achene of Siberian cocklebur health product water extract (SP-W) 63.1g, achene of Siberian cocklebur health product alcohol extract (SP-E) 48.8g, water is mentioned after achene of Siberian cocklebur health product alcohol
Object (SP-EW) 27.8g, totally six groups of xanthium sibiricums.
Embodiment two causes the influence of rat peritoneal mast cells degranulation release histamine to Compound 48/80
Extract rat peritoneal mast cells, arteria carotis sacrificed by exsanguination rat, with 75% alcohol disinfecting rat abdomen, ip
Hanks liquid 15ml gently massages rat abdomen 2min, cuts off abdominal cavity, draws peritoneal fluid into centrifuge tube, 1000r/min
(5 DEG C) centrifugation 5min of low temperature discard supernatant liquid, then primary with Hanks liquid washing cell, and Hanks liquid is added to be diluted to 80ml/ only.
It is 97.7% that trypan blue staining, which measures living cell rate, and it is 6.28% that Toluidine blue staining method, which measures mast cell purity,.It takes dilute
900 μ l of cell suspension after releasing is placed in 5ml EP pipe, and isometric Hanks liquid is added in self-controlled group, and 37 DEG C of pre-temperatures are incubated
10min；Achene of Siberian cocklebur each group extract 1ml (final concentration of 50 μ g/ml) is added in test group and self-controlled group, and positive controls add
Enter nasmil 1ml (final concentration of 200 μ g/ml), isometric Hanks liquid is added in model group and spontaneous release group；It is each after 10min
48,/80 100 μ l of Compound (final concentration of 2.5 μ g/ml) is added in test group, self-controlled group and model group, spontaneous release
Isometric Hanks liquid is added in group；EP pipe is transferred in ice-water bath after 10min, terminates reaction.Through 1000r/min low temperature (5 DEG C)
It is centrifuged 5min, takes supernatant 1ml into EP pipe, 1ml 0.1mol/l hydrochloric acid solution is added, adds 0.5ml 0.4mol/l hydrogen
Sodium hydroxide solution and 0.05% o-phthalaldehyde methanol solution of 0.1ml mix, and after (18-20 DEG C) placement 15min of room temperature, are added
0.5ml 0.5mol/l hydrochloric acid terminates reaction.Using fluorescence spectrophotometry, in excitation wavelength lambda ex 360nm, emission wavelength lambda em
Fluorescence intensity at 448nm calculates the concentration of histamine in cell supernatant according to standard curve and regression equation, and counts
Calculate histamine inhibiting rate.
Histamine inhibiting rate=(model group be averaged histamine release amount-test group be averaged histamine release amount)/model group averagely group
Amine burst size
The results show that model group has significant differences (P < 0.01) compared with spontaneous release group, show modeling at
Function can carry out next step experiment.Each administration group has significant differences (P < 0.01) compared with model group, shows grey
Ears or side handles of a utensil each group extract and positive drug, which can effectively inhibit Compound 48/80, stimulates rat peritoneal mast cells de-
Grain release histamine effect.More have two-by-two between six groups of extract groups of the achene of Siberian cocklebur significant differences (P < 0.01), and acts on
Effect is CP-E > SP-E > CP-W > SP-W > CP-EW > SP-EW, and pharmacodynamic results are shown in Table 1.
1 xanthium sibiricum of table to rat peritoneal mast cells release histamine influence (N=6)
Compared with model group group,﹡ ﹡P < 0.01
The foundation of three xanthium sibiricum HPLC chromatograms of embodiment
Chromatographic condition:
Chromatographic column is Zorbox SB-C18 chromatographic column (250mm × 4.6mm, 5 μm)；Mobile phase is acetonitrile (A) -0.2% second
Sour water (B), gradient elution (0~6min, 10%A；6~20min, 10%~31%A；20~25min, 31%~40%A)；Body
Product flow is 1.0ml/min；Detection wavelength is 254nm, and sample volume is 10 μ l.
It referring to fig. 2, is CP-W, CP-E, CP-EW, SP-W, SP-E, the chromatogram of SP-EW respectively from top to bottom.
In Fig. 2, substance expressed by number is respectively: 6- neochlorogenic acid, 7- caffeic acid cholinester, 8- chlorogenic acid, 9- are hidden green
Ortho acid, 10- achene of Siberian cocklebur thiazine diketone glycosides, 15- 3,4-Dicaffeoylquinic acid, 17- 3,5-Dicaffeoylquinic acid, 18- 4,5-Dicaffeoylquinic acid.
The analysis of example IV spectrum effect relationship
The peak area at each peak is as independent variable X using in HPLC map, using drug effect histamine inhibiting rate as dependent variable Y (table 2),
After initial data is standardized conversion, spectrum effect correlation analysis is carried out using partial least-squares regression method.It calculates respectively
Variable X corresponds to the regression coefficient of dependent variable Y, obtains regression equation of the X about Y.
Y=0.074X1+0.054X2+0.132X3+0.067X4+0.115X5+(-0.069)X6+0.208X7+0.215X8+(-
0.043)X9+0.193X10+(-0.175)X11+(-0.028)X12+(-0.011)X13+(-0.050)X14+(-0.063)X15+(-
0.073)X16+0.203X17+0.069X18。
2 xanthium sibiricum HPLC chromatogram peak area of table and drug effect value
Wherein X1, X2, X3, X4, X5, X7, X8, X10, X17, X18It is positively correlated with drug effect, X6, X9, X11, X12, X13, X14, X15,
X16It is negatively correlated with drug effect.By regression equation drug effect Y=coefficient1* peak area X1+ coefficient2* peak area X2+ ...+coefficient18* peak face
Product X18As can be seen that X depends on two factors of coefficient and peak area to the contribution rate of drug effect Y, choose that (coefficient is with Y positive correlation
Positive value) peak, with (+) coefficienti* peak area XiThe sum of be used as denominator, with each (+) coefficienti*XiAs molecule, six groups are obtained certainly
Variable X is to the drug effect contribution rate of Y, as shown in Figure 3.
The selection optimal extract of drug effect, that is, CP-E group is analyzed, and the drug effect contribution of anti-allergic effects is followed successively by X8
﹥ X10﹥ X7﹥ X3﹥ X1﹥ X17﹥ X18﹥ X2=X5﹥ X4, chromatographic peak X7(16.0%), X8(56.1%) and X10(18.0%) three is to drug effect
The sum of contribution rate accounts for 10 and is positively correlated the 90.1% of chromatographic peak with drug effect, chooses X7、X8、X10As " the drug effect tentatively confirmed
At grouping ".
Six chlorogenic acid of implementation case, caffeic acid cholinester and achene of Siberian cocklebur thiazine diketone glycosides assay
Chromatographic condition chromatographic column is Zorbox SB-C18 chromatographic column (250mm × 4.6mm, 5 μm)；Mobile phase is acetonitrile
(A) -0.2% acetic acid water (B), gradient elution (0~6min, 10%A；6~20min, 10%~31%A；20~25min, 31%
~40%A)；Volume flow is 1.0ml/min.Wherein test solution Detection wavelength is 254nm and 327nm, X7And X8Detect wave
A length of 327nm, X10Detection wavelength is 254nm；Test solution and X7、X8Reference substance solution sample volume is 10 μ l, control
Product solution X10Sample volume is 5 μ l.
It accompanies to compare using one point external standard method and calculates each component content in test solution, the results are shown in Table 3.
3 compound X of table7、X8、X10Content
The verifying of 7 drug effect of case study on implementation
Effect experiment is carried out according to identical method is studied with spectrum effect relationship, each compound dosage is equivalent to isodose
Achene of Siberian cocklebur CP-E extract.Arteria carotis sacrificed by exsanguination rat, with 75% alcohol disinfecting rat abdomen, ip Hanks liquid 15ml, gently
Forlement rat abdomen 2min cuts off abdominal cavity, draws peritoneal fluid into centrifuge tube, (5 DEG C) of 1000r/min low temperature centrifugations
5min discards supernatant liquid, then primary with Hanks liquid washing cell, and Hanks liquid is added to be diluted to 80ml/ only.Cell after taking dilution
900 μ l of suspension is placed in 5ml EP pipe, and isometric Hanks liquid is added in self-controlled group, and 37 DEG C of pre-temperatures incubate 10min；Test group, from
Each group drug 1ml is added in body control group and positive controls, and isometric Hanks liquid is added in model group and spontaneous release group；10min
48,/80 100 μ l of Compound (final concentration of 2.5 μ g/ml) is added in each test group, self-controlled group and model group afterwards, spontaneous
Isometric Hanks liquid is added in release group；EP pipe is transferred in ice-water bath after 10min, terminates reaction.Through 1000r/min low temperature
(5 DEG C) centrifugation 5min, take supernatant 1ml into EP pipe, and 1ml 0.1mol/l hydrochloric acid solution is added, adds 0.5ml
0.4mol/l sodium hydroxide solution and 0.05% o-phthalaldehyde methanol solution of 0.1ml mix, (18-20 DEG C) of room temperature placement
After 15min, 0.5ml 0.5mol/l hydrochloric acid is added and terminates reaction.Using fluorescence spectrophotometry, in excitation wavelength lambda ex
Fluorescence intensity calculates cell supernatant according to standard curve and regression equation at 360nm, emission wavelength lambda em 448nm
The concentration of middle histamine, and calculate histamine inhibiting rate.
Histamine inhibiting rate=(model group be averaged histamine release amount-test group be averaged histamine release amount)/model group averagely group
Amine burst size
4 drug effect confirmatory experiment result of table
Compared with model group group,﹡ ﹡P < 0.01
Drug effect confirmatory experiment shows as a result, each administration group has significant differences (P < 0.01) compared with model group
The rat peritoneal mast cells degranulation release histamine that each administration group can effectively inhibit the stimulation of Compound 48/80 is made
With.Comparison among groups have significant differences (P < 0.01), and each administration group inhibits rat peritoneal mast cells release histamine
The strong and weak sequence of effect is CP-E > effective component composition > caffeic acid cholinester (X7) > chlorogenic acid (X8) > achene of Siberian cocklebur thiazine pair
Ketoside (X10)。
Rat peritoneal mast cells degranulation is stimulated to discharge histamine Compound 48/80 with achene of Siberian cocklebur CP-E extract
Inhibiting rate as 100%, monomeric compound X7, X8, X10And combinations thereof histamine inhibiting rate and CP-E histamine inhibiting rate
Drug effect contribution rate of the ratio as each compound, available compound X7, X8, X10And combinations thereof drug effect contribution rate
(Fig. 2).Compound X is calculated by statistical method7, X8, X10Being to drug effect contribution rate is respectively 16.0%, 56.1%, 18.0%,
The sum of its drug effect contribution rate is 90.1%；Experiment measures compound X7, X8, X10Being to drug effect contribution rate is respectively 40.5%,
27.5%, 3.7%, the sum of drug effect contribution rate is 71.7%；The drug effect contribution rate of three's composition is 78.3%.
The above disclosure is only the preferred embodiments of the present invention, cannot limit the right model of the present invention with this certainly
It encloses, therefore equivalent changes made in accordance with the claims of the present invention, is still within the scope of the present invention.
Claims (4)
1. a kind of pharmaceutical composition for the antiallergic activity for substituting the achene of Siberian cocklebur, it is characterised in that: by chlorogenic acid, caffeic acid cholinester
It is formed with achene of Siberian cocklebur thiazine diketone glycosides.
2. a kind of pharmaceutical composition of antiallergic activity for substituting the achene of Siberian cocklebur according to claim 1, it is characterised in that: green
Ortho acid, caffeic acid cholinester, achene of Siberian cocklebur thiazine diketone glycosides mass ratio be 2.744:2.233:0.743.
3. a kind of application of composition as described in one of claim 1-2 in terms of preparing antiallergic activity drug.
4. application according to claim 3, it is characterised in that: the antiallergic activity drug further includes having other medically may be used
The drug ingedient or carrier of receiving, the mass ratio that the chlorogenic acid accounts for the antiallergic activity drug is 2.744%, caffeic acid gallbladder
The mass ratio that alkali ester accounts for the antiallergic activity drug is that 2.233%, achene of Siberian cocklebur thiazine diketone glycosides accounts for the antiallergic activity drug
Mass ratio is 0.743%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910318368.5A CN110038023B (en) | 2019-04-19 | 2019-04-19 | Anti-allergic pharmaceutical composition for replacing cocklebur fruit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910318368.5A CN110038023B (en) | 2019-04-19 | 2019-04-19 | Anti-allergic pharmaceutical composition for replacing cocklebur fruit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110038023A true CN110038023A (en) | 2019-07-23 |
| CN110038023B CN110038023B (en) | 2021-05-07 |
Family
ID=67277900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910318368.5A Active CN110038023B (en) | 2019-04-19 | 2019-04-19 | Anti-allergic pharmaceutical composition for replacing cocklebur fruit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110038023B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB887700A (en) * | 1958-08-28 | 1962-01-24 | Thomae Gmbh Dr K | Improvements in and relating to benzo-1:3-thiazinediones-(2:4) |
| KR20040026170A (en) * | 2002-09-23 | 2004-03-30 | 학교법인 경희대학교 | Lonicera japonica thunb |
| CN1994352A (en) * | 2005-03-28 | 2007-07-11 | 中国人民解放军第二军医大学 | Use of total glucosides extract of cocklebur fruit in preparation of product for resisting inflammatory reaction |
| KR20140137185A (en) * | 2013-05-22 | 2014-12-02 | 재단법인 한국한방산업진흥원 | Composition comprising an extract of combined crude drug including Angelicae Dahurica for preventing and treating inflammatory disease or allergic disease |
| CN105147656A (en) * | 2015-06-16 | 2015-12-16 | 洪铁 | Application of chlorogenic acid to preparing medicine for treating allergic rhinitis |
| US20160235800A1 (en) * | 2014-10-16 | 2016-08-18 | Eclipta LLC | Compositions for Reducing Environmental Sensitivity and Regulating Immune Function |
| CN108283643A (en) * | 2017-12-25 | 2018-07-17 | 中国人民解放军第二军医大学 | A kind of thiazadione class compound prepare prevent or the drug for the treatment of rheumatoid arthritis in application |
| CN108514568A (en) * | 2018-05-14 | 2018-09-11 | 黑龙江中医药大学 | The preparation method and its medical usage of thiazides compounds in the achene of Siberian cocklebur |
| CN108714147A (en) * | 2018-05-14 | 2018-10-30 | 杨真慧 | A kind of composition and its assay method preparing glioma treatment drug for substituting the achene of Siberian cocklebur |
-
2019
- 2019-04-19 CN CN201910318368.5A patent/CN110038023B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB887700A (en) * | 1958-08-28 | 1962-01-24 | Thomae Gmbh Dr K | Improvements in and relating to benzo-1:3-thiazinediones-(2:4) |
| KR20040026170A (en) * | 2002-09-23 | 2004-03-30 | 학교법인 경희대학교 | Lonicera japonica thunb |
| CN1994352A (en) * | 2005-03-28 | 2007-07-11 | 中国人民解放军第二军医大学 | Use of total glucosides extract of cocklebur fruit in preparation of product for resisting inflammatory reaction |
| KR20140137185A (en) * | 2013-05-22 | 2014-12-02 | 재단법인 한국한방산업진흥원 | Composition comprising an extract of combined crude drug including Angelicae Dahurica for preventing and treating inflammatory disease or allergic disease |
| US20160235800A1 (en) * | 2014-10-16 | 2016-08-18 | Eclipta LLC | Compositions for Reducing Environmental Sensitivity and Regulating Immune Function |
| CN105147656A (en) * | 2015-06-16 | 2015-12-16 | 洪铁 | Application of chlorogenic acid to preparing medicine for treating allergic rhinitis |
| CN108283643A (en) * | 2017-12-25 | 2018-07-17 | 中国人民解放军第二军医大学 | A kind of thiazadione class compound prepare prevent or the drug for the treatment of rheumatoid arthritis in application |
| CN108514568A (en) * | 2018-05-14 | 2018-09-11 | 黑龙江中医药大学 | The preparation method and its medical usage of thiazides compounds in the achene of Siberian cocklebur |
| CN108714147A (en) * | 2018-05-14 | 2018-10-30 | 杨真慧 | A kind of composition and its assay method preparing glioma treatment drug for substituting the achene of Siberian cocklebur |
Non-Patent Citations (6)
| Title |
|---|
| QIN L. ET AL: "A new thiazinedione from Xanthium strumarium", 《FITOTERAPIA》 * |
| 木村正康 编著: "《汉方药理学》", 31 August 2006, 中国医药科技出版社 * |
| 梁国鲁 等: "《金佛山野生药用植物资源》", 31 January 2013, 中国科学技术出版社 * |
| 程智 等: "苍耳子的化学成分", 《应用与环境生物学报》 * |
| 邱玉玲 等: "HPLC法测定苍耳子中苍耳子噻嗪双酮苷的含量", 《沈阳药科大学学报》 * |
| 邵海峰 等: "苍耳子抗过敏有效部位的实验研究", 《四川中医》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110038023B (en) | 2021-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101671617A (en) | Method for brewing pine pollen health wine | |
| CN101190280B (en) | Use of extract of non-fruit part of prune tree | |
| CN104531476B (en) | Health wine containing snow chrysanthemum and preparation method of health wine | |
| CN103877438B (en) | Traditional Chinese medicine preparation for treating gout and production method thereof | |
| CN110038023A (en) | A kind of pharmaceutical composition for the antiallergic activity substituting the achene of Siberian cocklebur | |
| CN109125516A (en) | One group of Herb Tea and its preparation method and application | |
| EP3141253A1 (en) | Compatible composition containing chinese medicine cichorium glandulosum boiss et hout as lipid-lowering active ingredient | |
| CN102228551A (en) | Chinese medicinal composition for preventing and treating injury of gastric mucosa and preparation method thereof | |
| CN103110100A (en) | Korean medical healthcare food composition as well as preparation method and application thereof | |
| CN108498590A (en) | A kind of natural hypoglycemic agent that can be improved bioavilability and avoid hyperchloremia | |
| CN114748534A (en) | Preparation method of cistanche salsa washed with wine | |
| CN105250440B (en) | A kind of lenitive Chinese medicine composition and its application | |
| CN104324090B (en) | A kind of general rhubarb anthraquinone capsule composition | |
| CN104606275B (en) | A kind of lipotropic traditional Chinese medicine effective ingredient compositionss | |
| CN106109767A (en) | A kind of compound preparation preventing and treating non-alcohol fatty liver | |
| TWI384994B (en) | Compositions for hypertension treatment | |
| CN109874891A (en) | A kind of tea plant preventing and treating hypertension | |
| CN105168160B (en) | A kind of tablet of antelope's horn for common cold and preparation method thereof | |
| CN102204990A (en) | Couplet medicine extract for reducing sugar content and preventing diabetic angiopathy and preparation method thereof | |
| CN102961690B (en) | Drug composition used for preventing hypertension complications and application thereof | |
| CN108478706A (en) | It is a kind of to protect cardiovascular composition and preparation method thereof | |
| CN105267619B (en) | The anti-tumor Chinese medicine compound extract that a kind of suppression ras proto-oncogenes are overexpressed | |
| CN108079169A (en) | For preventing and treating the Chinese medicine composition of atherosclerosis and its complication, Chinese medicine preparation and application | |
| CN108148716A (en) | A kind of arborvitae health-preserving medicinal liquor | |
| CN104013614B (en) | A kind of golden larch lactone H preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |